Companies › Kartos Therapeutics
1 active drug program in 6 registered trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Navtemadlin (KRT-232) Tumour suppressor p53/oncoprotein Mdm2 inhibitor | TP53, MDM2 | Phase 3 | Myelofibrosis; Polycythemia Vera; Endometrial Cancer; Diffuse Large B Cell Lymphoma … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03669965 | Navtemadlin (KRT-232) | Phase 2 | Polycythemia Vera | Oncology | Apr 2022 |
| NCT04502394 | Navtemadlin (KRT-232) | Phase 1 | Diffuse Large B Cell Lymphoma | Oncology | Oct 2022 |
| NCT06479135 | Navtemadlin (KRT-232) | Phase 3 | Myelofibrosis | Oncology | Dec 2026 |
| NCT04190550 | Navtemadlin (KRT-232) | Phase 1 | Acute Myeloid Leukemia | Oncology | Jun 2027 |
| NCT03041688 | Navtemadlin (KRT-232) | Phase 1 | Acute Myeloid Leukemia | Oncology | Jun 2027 |
| NCT05797831 | Navtemadlin (KRT-232) | Phase 2 | Endometrial Cancer | Oncology | Jul 2027 |
LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.